INFINITY Phase 2 Trial for DME Patients

The INFINITY Phase 2 trial is a randomized, active comparator-controlled trial evaluating a single intravitreal injection of ADVM-022 gene therapy candidate in patients with diabetic macular edema (DME), the leading cause of vision loss among patients with diabetic retinopathy (DR).

Company
learn more
Pipeline
learn more
Platform
learn more
Careers
learn more

News

May 28 2020
Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results
May 21 2020
Adverum Biotechnologies to Host a Conference Call and Webcast to Report First Quarter 2020 Financial Results and Provide Corporate Update
May 04 2020
Adverum Biotechnologies Reports Positive Interim Data from Cohorts 1-3 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD